The lights are on and phones working....
Despite the sentiment voiced here that the company is no longer responsive to phone calls, I did get thru easily and was told that they are trying to talk to all investors. But, don't expect answers to the types of questions being asked repeatedly here.
No real significant news to me except for confirmation that a second CRO has been hired, obviously an unanticipated expense that has caused some employees to once again opt to defer paychecks in order to pay the CRO. The company believes that the data has not been analyzed in any way that would prevent a valid audit, and that they are in accordance with FDA guidelines for such an audit. So, there is still a sense of hope and no bridges burned. FWIW, the idea of launching without FDA approval is only one of many options if the phase III studies turn out to be inadequate for approval.
So, back to waiting.
